| |
Patients (n)
|
Median mPITX2 (%)
|
mPITX2
low
|
mPITX2
high
|
p value
|
|---|
|
All patients
|
498 (100 %)
|
32.9
| | | |
|
Mean/median follow-up (months)
|
22/16
| | | | |
|
Age (years)
| | | | |
0.001a
|
|
≤60
|
224 (45.0 %)
|
31.0
|
128 (57.1 %)
|
96 (42.9 %)
| |
|
>60
|
274 (55.0 %)
|
35.2
|
135 (49.1 %)
|
140 (50.9 %)
| |
|
Unknown
|
0 (0.0 %)
| | | | |
|
T category
| | | | |
0.043a
|
|
pT1/2
|
188 (37.8 %)
|
25.7
|
137 (70.3 %)
|
58 (29.7 %)
| |
|
pT3/4
|
293 (58.8 %)
|
37.5
|
126 (41.4 %)
|
178 (58.6 %)
| |
|
Unknown
|
17 (3.4 %)
| | | | |
|
ISUP Gleason grading group
| | | | |
<0.001b
|
|
1 (<7)
|
45 (9 %)
|
28.0
|
31 (68.9 %)
|
14 (31.1 %)
| |
|
2 (3 + 4)
|
147 (29.5 %)
|
28.6
|
95 (64.2 %)
|
53 (35.8 %)
| |
|
3 (4 + 3)
|
101 (20.3 %)
|
31.5
|
55 (54.5 %)
|
46 (45.5 %)
| |
|
4 (=8)
|
64 (12.9 %)
|
34.1
|
33 (51.6 %)
|
31 (48.4 %)
| |
|
5 (>8)
|
141 (28.3 %)
|
41.0
|
49 (34.8 %)
|
92 (65.2 %)
| |
|
Unknown
|
0 (0.0 %)
| | | | |
|
Surgical margin
| | | | |
<0.001a
|
|
R0
|
318 (63.9 %)
|
30.8
|
180 (56.8 %)
|
137 (43.2 %)
| |
|
R1
|
152 (30.5 %)
|
37.0
|
68 (44.7 %)
|
84 (55.3 %)
| |
|
Unknown
|
28 (5.6 %)
| | | | |
|
Nodal status
| | | | |
0.19a
|
|
pN0
|
349 (70.1 %)
|
32.3
|
184 (53.0 %)
|
163 (47.0 %)
| |
|
pN1
|
79 (15.8 %)
|
36.6
|
32 (40.5 %)
|
47 (49.5 %)
| |
|
Unknown
|
70 (14.1 %)
| | | | |
|
Pre-surgical PSA (ng/ml)
| | | | |
0.36b
|
|
0–4
|
53 (10.6 %)
|
29.5
|
31 (58.5 %)
|
122 (41.5 %)
| |
|
4–10
|
286 (57.5 %)
|
32.9
|
150 (52.4 %)
|
136 (47.6 %)
| |
|
>10
|
156 (31.3 %)
|
34.3
|
79 (50.3 %)
|
78 (49.7 %)
| |
|
Unknown
|
3 (0.6 %)
| | | | |
|
ERG fusionc
| | | | |
<0.001a
|
|
Negative
|
178 (35.8 %)
|
28.0
|
122 (62.9 %)
|
66 (37.1 %)
| |
|
Positive
|
152 (30.5 %)
|
37.2
|
69 (45.4 %)
|
83 (54.6 %)
| |
|
Unknown
|
168 (33.7 %)
| | | | |
|
AR score
| | | | |
0.15a
|
|
Negative
|
246 (49.4 %)
|
30.6
|
140 (56.9 %)
|
106 (43.1 %)
| |
|
Positive
|
84 (16.9 %)
|
34.6
|
41 (48.8 %)
|
43 (51.2 %)
| |
|
Unknown
|
186 (33.7 %)
| | | | |
-
mPITX2 in the validation cohort is described elsewhere [30]. mPITX2 was dichotomized by the respective optimized cutoff into mPITX2
low vs. mPITX2
high
-
aWilcoxon-Mann-Whitney test
-
bKruskal-Wallis test
-
cERG fusion status as adopted from The Cancer Genome Atlas Research Network (2015) [27]
